Human Insulin Market worth 39.13 Billion USD by 2020 Human Insulin Market worth 39.13 Billion USD by 20 | Page 17

TABLE OF CONTENTS
14 COMPANY PROFILES............................................................................................................... 139
•( Overview, Financials, Products & Services, Strategy, & Developments)*
• 14.1
INTRODUCTION............................................................................................................................................................. 139
• 14.2
B. BRAUN MELSUNGEN AG........................................................................................................................................... 143
• 14.3
BECTON, DICKINSON AND COMPANY.......................................................................................................................... 145
• 14.4
BIOCON LIMITED........................................................................................................................................................... 148
• 14.5
BIODEL INC.................................................................................................................................................................... 151
• 14.6
ELI LILLY AND COMPANY.............................................................................................................................................. 152
• 14.7
JULPHAR( ALSO KNOWN AS GULF PHARMACEUTICAL INDUSTRIES)........................................................................ 158
• 14.8
NOVO NORDISK A / S...................................................................................................................................................... 160
• 14.9
SANOFI........................................................................................................................................................................... 166
• 14.10
WOCKHARDT LIMITED.................................................................................................................................................. 170
• 14.11
YPSOMED AG................................................................................................................................................................ 172
• * Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.
15
APPENDIX................................................................................................................................ 175
• 15.1
INSIGHTS OF INDUSTRY EXPERTS............................................................................................................................... 175
• 15.2
DISCUSSION GUIDE...................................................................................................................................................... 176
• 15.3
INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE.............................................................................................. 181
• 15.4
AVAILABLE CUSTOMIZATIONS...................................................................................................................................... 181
• 15.5
RELATED REPORTS........................................................................................................................................................ 182
sales @ marketsandmarkets. com www. marketsandmarkets. com
17